Residency · Residency · Medicine-Pediatrics
Obesity Medicine: A Lifespan Approach
Overview
Obesity is a chronic, relapsing, multifactorial disease affecting both children and adults with increasing prevalence worldwide. Pediatric obesity prevalence in the US: ~20% of children aged 2-19 years; adult prevalence: ~42%. Developmental origins of obesity begin in utero and early childhood, making the Med-Peds perspective uniquely valuable. Management requires a comprehensive approach integrating behavioral, pharmacologic, and surgical interventions across the lifespan.
Definitions and Classification
Pediatric (Ages 2-18)
Overweight: BMI 85th-94th percentile for age and sex. Obesity: BMI >= 95th percentile. Severe obesity: BMI >= 120% of 95th percentile or BMI >= 35 (whichever is lower) BMI z-scores used for tracking in research; percentiles used clinically. Under age 2: weight-for-length charts; no BMI-based definitions.
Adult (Age >= 18)
Overweight: BMI 25-29.9 kg/m2. Obesity Class I: BMI 30-34.9. Obesity Class II: BMI 35-39.9. Obesity Class III: BMI >= 40. BMI does not account for muscle mass, body composition, or fat distribution. Waist circumference adds cardiovascular risk information (>102 cm men, >88 cm women)
Developmental Origins and Risk Factors
Early Life Programming
Maternal obesity, gestational diabetes, and excessive gestational weight gain increase offspring obesity risk. Rapid infant weight gain ("catch-up growth") in the first 2 years is a strong predictor. Breastfeeding is modestly protective. Adiposity rebound: normally occurs at age 5-6; early rebound (before age 5) predicts later obesity.
Genetic and Epigenetic Factors
Heritability of BMI estimated at 40-70%. Monogenic obesity: rare but important (leptin deficiency, MC4R mutations, POMC deficiency, Bardet-Biedl syndrome) Syndromic obesity: Prader-Willi, Albright hereditary osteodystrophy, Beckwith-Wiedemann. Polygenic risk: >900 common variants with small individual effects. Epigenetic modifications from early environmental exposures (nutrition, stress, toxins)
Environmental and Behavioral Factors
Energy-dense food environment, sugar-sweetened beverages. Sedentary behavior, screen time (AAP recommends <1 hour/day for ages 2-5, consistent limits for older children) Sleep deprivation (associated with obesity in both children and adults) Adverse childhood experiences (ACEs) and chronic stress. Socioeconomic disparities: obesity disproportionately affects low-income and minority populations. Food insecurity paradoxically associated with obesity.
<image>Infographic showing the developmental trajectory of obesity risk factors from prenatal period through adulthood including critical windows of intervention</image>
Screening and Assessment
Pediatric Screening
BMI calculated and plotted at every well-child visit starting at age 2. Growth chart trajectory more informative than single measurements. Screen for comorbidities when BMI >= 85th percentile: fasting lipids, glucose, ALT, blood pressure. Evaluate for secondary causes if obesity is early-onset (<5 years), severe, or accompanied by developmental delay, short stature, or dysmorphic features.
Adult Screening
BMI at every primary care visit. Waist circumference measurement when BMI 25-35. Metabolic syndrome screening: fasting glucose/A1c, lipid panel, blood pressure. Screen for OSA (STOP-BANG), NAFLD (ALT), PCOS in women, hypogonadism in men. Assess for eating disorders (binge eating disorder is common and underdiagnosed)
Motivational Interviewing Across Ages
Non-judgmental, patient-centered communication essential. Avoid stigmatizing language: use "unhealthy weight" rather than "fat" or "obese" when speaking to patients. With children: engage parents as agents of change without blaming. With adolescents: build autonomy, explore readiness for change, address body image. With adults: explore ambivalence, set collaborative goals, use reflective listening.
Behavioral and Lifestyle Interventions
Pediatric Approach
Family-based behavioral therapy is the cornerstone (evidence strongest for ages 6-12) Structured programs with 26+ contact hours show best outcomes. AAP 2023 guidelines emphasize intensive health behavior and lifestyle treatment (IHBLT) as first-line. Dietary focus: reduce sugar-sweetened beverages, increase fruits/vegetables, family meals, portion control. Physical activity: 60 min/day moderate-vigorous for children >= 6 years. Screen time limits and sleep hygiene.
Adult Approach
Comprehensive lifestyle intervention: 500-750 kcal/day deficit, 150-300 min/week moderate activity. Behavioral strategies: self-monitoring, stimulus control, cognitive restructuring. Structured programs (e.g., DPP-based) with regular follow-up. Dietary patterns: Mediterranean, DASH, low-carbohydrate, and intermittent fasting all show similar modest weight loss. 5-10% weight loss produces clinically meaningful improvements in metabolic parameters.
<image>Staged approach to obesity management in pediatrics showing escalation from prevention counseling through intensive behavioral therapy, pharmacotherapy, and bariatric surgery based on BMI severity and age</image>
Pharmacotherapy
Pediatric Pharmacotherapy (Ages 12+)
| Agent | Approved Age | Weight Loss | Key Notes |
|---|---|---|---|
| Semaglutide (Wegovy) | ≥12 years | ~16% body weight | STEP TEENS trial |
| Liraglutide (Saxenda) | ≥12 years | ~5% BMI reduction | GLP-1 RA, daily injection |
| Phentermine | ≥16 years | Variable | Short-term only (max 12 weeks) |
| Orlistat | ≥12 years | Modest | GI side effects limit use |
| Setmelanotide | ≥6 years | Variable | Only for monogenic obesity (POMC, PCSK1, LEPR) |
Semaglutide (Wegovy): FDA-approved for ages >= 12 with obesity; ~16% body weight reduction in STEP TEENS trial. Liraglutide (Saxenda): FDA-approved for ages >= 12; ~5% BMI reduction. Phentermine: FDA-approved for ages >= 16 (short-term, max 12 weeks) Orlistat: FDA-approved for ages >= 12; limited efficacy and GI side effects limit use. Setmelanotide: for rare monogenic obesity (POMC, PCSK1, LEPR deficiency); ages >= 6. AAP 2023 guidelines recommend offering pharmacotherapy to children >= 12 with obesity alongside behavioral intervention.
Adult Pharmacotherapy
Semaglutide 2.4 mg weekly: ~15-17% weight loss; also cardiovascular benefit (SELECT trial) Tirzepatide (Zepbound): dual GIP/GLP-1 agonist; ~20-22% weight loss in SURMOUNT trials. Phentermine-topiramate ER: ~10% weight loss; contraindicated in pregnancy (topiramate teratogenicity) Naltrexone-bupropion: ~5-6% weight loss; avoid in seizure disorders, eating disorders. Orlistat: ~3-5% weight loss; GI side effects, fat-soluble vitamin malabsorption. Weight regain is expected after medication discontinuation — chronic treatment paradigm. Cost and insurance coverage remain major barriers.
Special Considerations
GLP-1 agonists: nausea/vomiting most common side effect; rare risk of pancreatitis, gallbladder disease. Thyroid C-cell tumor signal in rodents (not confirmed in humans); avoid in MEN2 or medullary thyroid cancer history. Adolescents on GLP-1 agonists need monitoring of growth, nutritional adequacy, and psychological impact. Contraception counseling for adolescent females (GLP-1 agonists may reduce oral contraceptive efficacy)
Bariatric and Metabolic Surgery
Pediatric Bariatric Surgery
AAP and ASMBS recommend evaluating adolescents >= 13 with severe obesity (BMI >= 40 or >= 35 with comorbidities) for metabolic surgery. Sleeve gastrectomy: most commonly performed in adolescents; ~25-30% total weight loss. Roux-en-Y gastric bypass: greater weight loss and diabetes remission but higher complication rate. Teen-LABS data: durable weight loss at 5-8 years, significant improvement in comorbidities. Nutritional monitoring critical: iron, B12, calcium, vitamin D, folate. Psychosocial screening mandatory; patients need lifelong follow-up.
Adult Bariatric Surgery
Indications: BMI >= 40 or BMI >= 35 with comorbidities (2022 ASMBS/IFSO guidelines lowered to BMI >= 35 or >= 30 with comorbidities) Sleeve gastrectomy surpassed RYGB as most common procedure. T2DM remission rates: 60-80% at 5 years. Mortality benefit demonstrated in long-term cohort studies. Consider in patients who have not achieved adequate weight loss with behavioral and pharmacologic therapy.
<image>Anatomical diagrams comparing sleeve gastrectomy and Roux-en-Y gastric bypass with key physiologic effects including gut hormone changes, caloric restriction, and malabsorption</image>
Comorbidity Management
Metabolic Complications
Type 2 diabetes: increasingly diagnosed in adolescents (TODAY trial showed aggressive beta-cell decline in youth) Dyslipidemia: lifestyle first; statins for high-risk pediatric patients >= 10 years. Hypertension: percentile-based in children; treat if stage 2 or stage 1 with target organ damage. NAFLD/MASLD: weight loss is the primary treatment; no approved pharmacotherapy in children.
Other Comorbidities
Obstructive sleep apnea: screen with polysomnography; CPAP or weight loss. PCOS in adolescent and adult females. Slipped capital femoral epiphysis and Blount disease in obese children. Depression and anxiety: bidirectional relationship with obesity. Weight stigma and bullying contribute to psychological morbidity.
Clinical Pearls
BMI percentiles plateau at higher values; a child at the 99th percentile can gain substantial weight without a change in percentile — use percent of the 95th percentile or absolute BMI for severe obesity tracking. Early-onset severe obesity (before age 5) with hyperphagia warrants genetic testing (leptin, MC4R, Prader-Willi) Weight regain after GLP-1 agonist discontinuation is the rule, not the exception — counsel patients about chronic disease management. Bariatric surgery in adolescents has comparable or better outcomes than in adults; delay may worsen comorbidities. Screen all obese children for NAFLD with ALT starting at age 9-11 (or earlier if risk factors present) The language used to discuss weight profoundly affects patient engagement; "person-first" language is recommended.
<image>Flowchart for evaluation of obesity in a child including when to suspect secondary or syndromic causes versus exogenous obesity based on growth pattern, developmental history, and physical examination findings</image>
References
- Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023;151(2):e2022060640.
- Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Inge TH, Courcoulas AP, Jenkins TM, et al. Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults. N Engl J Med. 2019;380(22):2136-2145.
- Lister NB, Baur LA, Felix JF, et al. Child and Adolescent Obesity. Nat Rev Dis Primers. 2023;9(1):24.
How to think about this
Obesity is a complex, chronic disease requiring a comprehensive, lifelong approach. It’s not simply a matter of willpower, but an interaction of genetics, environment, and biology. As a Med-Peds resident, you are uniquely positioned to intervene across the lifespan, recognizing the developmental origins of obesity and the continuity of care needed from childhood into adulthood. Your role is not just about treatment, but about prevention, early identification, and compassionate, non-stigmatizing communication that empowers patients and families to make sustainable changes. Understanding the different treatment modalities—lifestyle, pharmacotherapy, and surgery—and when to apply them across age groups is key to effective management.
Check yourself with 2 bullets.
- What are the key differences in defining obesity in pediatric versus adult populations, and why are these distinctions important for your clinical practice?
- When considering pharmacotherapy for obesity, what are two major considerations for both adolescents and adults regarding efficacy, side effects, and long-term management?
